Buffett smells opportunity in Tylenol mis-manufacturing

Apparently GMP violations have an odor detectable by high-stakes investors as well as the FDA. Warren Buffet is taking his eye off of Genzyme CEO Henri Termeer for the moment and casting it toward Johnson & Johnson and Bill Weldon.

Berkshire Hathaway has upped its stake in J&J by about 18 million shares. The move fits the Buffet "investment thesis," reports TheStreet: The stock price is depressed, off about $20 per share, trading at about $59 on Tuesday.

A Morningstar analyst attributes the weakness to the recent black eye the company is suffering from the Tylenol recalls. Still, the OTC business is just one percent of J&J sales. The impact is expected be short term and likely to be corrected within two years, according to the article. Perhaps not all analysts are aware of the pace in a GMP-violation comeback.

Termeer of Genzyme just recently made a peace of sorts with Buffett, but only after some board changes appeased him.

- see the article

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.